Elsiglutide

DB06336InvestigationalSmall molecule

Investigated for use/treatment in diarrhea and adverse effects (chemotherapy).

Mechanism: ZP 1846 is a glucagon-like peptide-2 (GLP-2) analogue, a peptide growth factor that specifically targets and stimulates growth of the intestinal epithelium.
Curator reviewed
Primary indication: Investigated for use/treatment in diarrhea and adverse effects (chemotherapy).Curator reviewed
Code names: ZP-1846

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Elsiglutide, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.